Web14 feb 2024 · In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall … WebThe plenary presentation on the ASAP trial in acute myeloid leukemia (AML) does just that. Funded by a non-profit group, this pivotal study questioned the utility of salvage …
Paper: In Patients with Relapsed/Refractory AML Sequential …
Web10 dic 2024 · The findings from the phase 3 ASAP trial (NCT02461537) showed that the primary end point of disease-free survival (DFS) at day 56 was reached by 84.1% of those in the disease control (DISC) arm (n = 139) and 81.3% of those in the remission induction strategy (RIST) arm (n = 137; test for noninferiority, P = .047). Web10 dic 2024 · The ASAP trial enrolled 281 patients with AML, including 183 with poor responses after their first induction therapy. Half of the patients were randomized to the disease-control arm and proceeded directly to allo-HCT without attempts to induce CR. beagamestar
Intensive Remission Induction Chemotherapy Prior to alloHCT …
WebThe clinical trial compared the standard treatment with an alternative approach for high-risk AML patients. The goal of the randomized controlled trial led by Prof. Schetelig was to get patients to transplantation as soon as possible. This coined the name of this trial: ASAP. Web23 lug 2024 · The novel agent, eprenetapopt (APR-246) combined with azacitidine (Vidaza) has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treated in a phase 2 study (NCT03588078), Aprea Therapeutics, Inc, announced, in a press release. Web15 feb 2024 · Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML). Objectively reviewing past and current knowledge aids guiding future research. Therefore, we provide a ... dg4j